Trius Therapeutics' Antibiotic Tedizolid Demonstrates High Efficacy in Patients With Cellulitis

SAN DIEGO, April 2, 2012 (GLOBE NEWSWIRE) -- Trius Therapeutics, Inc. (Nasdaq:TSRX) announced today the results of a subgroup analysis from its first Phase 3 investigational study (TR701-112 Trial) in Acute Bacterial Skin and Skin Structure Infections (ABSSSI) at the European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) meeting in London. The data demonstrated that patients with severe cellulitis displayed higher clinical response rates following 6 days of treatment with a single 200 milligram daily dose of oral tedizolid phosphate than those treated for 10 days with two 600 milligram daily doses of oral linezolid.